Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Doxorubicin and cyclophosphamide (AC) + bevacizumab
DRUG: Docetaxel (T) + bevacizumab
DRUG: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
DRUG: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
DRUG: Bevacizumab and trastuzumab maintenance therapy
DRUG: Bevacizumab maintenance therapy

Sponsor

Sanofi